GWM
FPRX

Gupta Wealth Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Gupta Wealth Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-100
Closed -$4K – 1318
2015
Q4 		$4K Buy
+100
New +$3.35K ﹤0.01% 1064

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Gupta Wealth Management's FPRX Position: Q1 2016 in Review

Gupta Wealth Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2016, closing a stake of 100 shares — an estimated $4K sold.

Gupta Wealth Management first reported a position in FPRX in Q4 2015 and held it in 1 quarter. The position peaked at $4K in Q4 2015. 140 funds tracked by Wall St. Rank hold FPRX as of Q1 2016.

  • Gupta Wealth Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Gupta Wealth Management sold 100 Five Prime Therapeutics, Inc. shares in Q1 2016, an estimated $4K.
  • Gupta Wealth Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Gupta Wealth Management's Five Prime Therapeutics, Inc. position peaked at $4K in Q4 2015.
  • 140 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2016.

Based on Gupta Wealth Management's 13F filing for Q1 2016, filed 16 May 2016.